Interstitial lung diseases
Symposium
Progressive pulmonary fibrosis: challenges and controversies
Translational
Aims : to describe the magnitude of the problem of progressive pulmonary fibrosis (PPF); to discuss the diagnostic tools to detect or predict PPF; to explore some of the putative pathogenic mechanisms that may be involved in the progression of fibrotic lung disorder; to discuss the therapeutic approach, covering immunosuppression and antifibrotic drugs, antifibrotic drugs alone, nonpharmacological support, and when to start and stop this all.
Target audience :
Adult pulmonologist/Clinician, Clinical researcher, Medical Student, Nurse, Pathologist, Patient, Physician in Pulmonary Training, Physiologist, Radiologist, Respiratory physiotherapist, Scientist (basic, translational)
Methods :
Cell and molecular biology, Imaging, Pulmonary function testing
08:30
Patient's perspective
E. Robertson(Maidenhead, United Kingdom)
COI
1
673
08:35
Progressive pulmonary fibrosis. The burden of disease progression in fibrotic interstitial lung disease
P. Molyneaux(London, United Kingdom)
COI
-
Description
2
674
08:50
Diagnostic challenges and biomarkers to profile progression. Time is gold
A. Podolanczuk(New York, United States)
COI
-
Description
3
675
09:05
Cellular and molecular mechanisms involved in progression of pulmonary fibrosis
M. Selman Lama(Mexico, Mexico)
COI
-
Description
4
676
09:20
Therapeutic approach and challenges in PPF
E. Bendstrup(Aarhus N, Denmark)
COI
-
Description
5
677
09:35
Discussion and Q&A
6
678
. . .